Variant Pharmaceuticals Has a New Name - ZyVersa Therapeutics, Inc.

WESTON, Fla., May 1, 2019 /PRNewswire/ -- Variant Pharmaceuticals, Inc., a clinical  stage specialty biopharmaceutical company developing  first-in-class drugs for patients with high unmet medical needs, is  pleased to announce that we have changed our name to ZyVersa Therapeutics effective immediately.

"As our company has evolved, we felt it was important to rebrand it with a name that expresses our vision, our transforming pipeline, and our entrepreneurial spirit," stated Stephen C. Glover, Variant's Co-founder and Chief Executive Officer. "ZyVersa, which was derived from the word versatility, reflects the diverse therapeutic area expertise of our highly experienced leadership team, and our openness to new ideas required to be on the forefront of medical innovation.  It is consistent with our lead pipeline assets, 2HPβCD and our unique inflammasome inhibitor, each of which have potential for multiple indications. And, it conveys our forward-thinking mindset."

Along with our name change, we are revealing our newly designed corporate logo and our website domain name change: www.zyversa.com.                                                               

About ZyVersa Therapeutics, Inc.

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have high unmet medical needs. Our clinical pipeline includes a phase 2a-ready asset, VAR 200, a cholesterol efflux mediator for treatment of focal segmental glomerulosclerosis (FSGS), and a novel inflammasome inhibitor with potential for multiple inflammatory diseases. For more information, please visit www.zyversa.com.

SOURCE Variant Pharmaceuticals, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED